Abstract
A pharmacodynamic model is proposed and equations are developed for the quantitative analysis of dose-time-cell-survival curves produced by the administration of cell-cycle-specific chemo-therapeutic agents. The essential feature of the model is an irreversible, bimolecular mechanism of drug-receptor interaction which serves as the interface between the pharmacokinetics of the drug and the cell-cycle-cell-proliferation kinetics of the normal and neoplastic cells. A preliminary cell system which allows adequate characterization of the experimental data is a two-compartment model where cells are assumed to exist in their proliferative and nonproliferative phases. The chemotherapeutic model was used to analyze dose-time-cell-survival curves found in the literature for the effects of vincristine, vinblastine, arabinosylcytosine, and cyclophosphamide on lymphoma and hematopoietic cells in the mouse femur. Similarity in the values of the “cell-kill” constants for these drugs on the two cell types indicates that, in the cell systems studied, the proliferative state of the cells is the primary in vivodeterminant of selective chemotherapy.
Similar content being viewed by others
References
H. E. Skipper. The cell cycle and chemotherapy of cancer. In R. Baserga (ed.),The Cell Cycle and Cancer, Marcel Dekker, New York, pp. 358–387 (1971).
W. J. Jusko. Pharmacodynamics of chemotherapeutic effects: Dose-time-response relationships for phase-nonspecific agents.J. Pharm. Sci.,60, 892–895 (1971).
W. J. Jusko. Pharmacokinetic principles in pediatric pharmacology.Pediat. Clin. N. Am.,19, 81–100 (1972).
L. Simpson-Herren, and H. H. Lloyd. Kinetic parameters and growth curves for experimental tumor systems.Cancer Chemotherap. Rep. Part 1,54, 143–174 (1970).
R. L. Dedrick, D. D. Forrester, and D. H. W. Ho.In vitro-In vivo correlation of drug metabolism-Deamination of 1-β-d-arabinofuranosylcytosine.Biochem. Pharmacol.,21, 1–16 (1972).
IBM Scientific Subroutine RKGS, 360A-CM-03X, Version III. IBM Technical Publications Department, White Plains, N.Y. (1968).
W. R. Bruce, and B. E. Meeker. Dissemination and growth of transplanted isologous murine lymphoma cells.J. Natl. Cancer Inst.,32, 1145–1159 (1964).
F. A. Valeriote, and W. R. Bruce. Comparison of the sensitivity of hematopoietic colony-forming cells in different proliferative states to vinblastine.J. Natl. Cancer Inst.,38, 393–399 (1967).
W. R. Bruce, B. E. Meeker, W. E. Powers, and F. A. Valeriote. Comparison of the dose-and time-survival curves for normal hematopoietic and lymphoma colony-forming cells exposed to vinblastine, vincristine, arabinosylcytosine, and amethopterin.J. Natl. Cancer Inst.,42, 1015–1023 (1969).
W. R. Bruce, and F. A. Valeriote. Normal and malignant stem cells and chemotherapy.Ann. Symp. Fund. Cancer Res., pp. 409–122 (1967).
C. M. Metzler. NONLIN. Technical Report No. 7292/69/7293/005, Upjohn, Kalamazoo, Mich. (1969).
F. A. Valeriote, and W. R. Bruce. Anin vitro assay for growth-inhibiting activity of vinblastine.J. Natl. Cancer Inst.,35, 851–856 (1965).
K. B. Bischoff, K. J. Himmelstein, R. L. Dedrick, and D. S. Zaharko. Pharmacokinetics and cell population growth models in cancer chemotherapy.ACS Advan. Chem., in press (1972).
K. B. Bischoff, R. L. Dedrick, D. S. Zaharko, and J. A. Longstreth. Methotrexate pharmacokinetics.J. Pharm. Sci.,60, 1128–1133 (1971).
C. F. Evert, and M. J. Randall. Formulation and computation of compartment models.J. Pharm. Sci.,59, 403–409 (1970).
G. M. Hahn. A formalism describing the kinetics of some mammalian cell populations.Math. Biosci.,6, 295–304 (1970).
S. I. Rubinow, J. L. Lebowitz, and A.-M. Sapse. Parameterization ofin vivo leukemic cell populations.Biophys. J.,11, 175–188 (1971).
W. C. Werkheiser. Mathematical simulation in chemotherapy.Ann. N.Y. Acad. Sci.,186, 343–358 (1971).
W. C. Werkheiser, G. B. Grindley, R. G. Moran, and C. A. Nichol. Mathematical simulation of the interaction of drugs which inhibit DNA biosynthesis.Mol. Pharmacol.,9, 320–329 (1973).
K. J. Himmelstein and K. B. Bischoff. Mathematical representations of cancer chemotherapy effects.J. Pharmacokin. Biopharm.,1, 51–68 (1973).
K. J. Himmelstein and K. B. Bischoff. Models of ARA-C chemotherapy of L1210 leukemia in mice,J. Pharmacokin. Biopharm.,1, 69–81 (1973).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jusko, W.J. A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents. Journal of Pharmacokinetics and Biopharmaceutics 1, 175–200 (1973). https://doi.org/10.1007/BF01062346
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01062346